Literature DB >> 17703260

Safety and efficiency of recombinant activated factor VII in postcardiotomy massive hemorrhage.

Yoan Lamarche1, Philippe Demers, Nancy C Poirier, Danielle Robitaille, Raymond Cartier.   

Abstract

Postoperative massive hemorrhage is a difficult clinical situation after cardiac surgery. Recombinant activated factor VII (rf-VIIa) can be a useful adjunct to surgical hemostasis and blood product transfusion. Four cases of massive hemorrhage treated with rf-VIIa after complex cardiac surgery are reported. A review of the literature and possible guidelines for the use of rf-VIIa in cardiac surgery are provided.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17703260      PMCID： PMC2651387          DOI： 10.1016/s0828-282x(07)70832-2

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN： 0828-282X            Impact factor:   5.223


  25 in total

1.  Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery.

Authors:  Wulf Dietrich; Michael Spannagl
Journal:  Anesth Analg       Date:  2002-05       Impact factor: 5.108

Review 2.  Potential role for rFVIIa in transfusion medicine.

Authors:  Ulla Hedner; Elisabeth Erhardtsen
Journal:  Transfusion       Date:  2002-01       Impact factor: 3.157

3.  Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery.

Authors:  Christian von Heymann; H Hotz; W Konertz; W J Kox; C Spies
Journal:  J Cardiothorac Vasc Anesth       Date:  2002-10       Impact factor: 2.628

4.  Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial.

Authors:  Philip W Friederich; Christiaan P Henny; Embert J Messelink; Mark G Geerdink; Tymen Keller; Karl-Heinz Kurth; Harry R Büller; Marcel Levi
Journal:  Lancet       Date:  2003-01-18       Impact factor: 79.321

5.  Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII.

Authors:  Jack D Bui; George D Despotis; Elbert P Trulock; G Alexander Patterson; Lawrence T Goodnough
Journal:  J Thorac Cardiovasc Surg       Date:  2002-10       Impact factor: 5.209

6.  Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study.

Authors:  P Diprose; M J Herbertson; D O'Shaughnessy; R S Gill
Journal:  Br J Anaesth       Date:  2005-09-23       Impact factor: 9.166

Review 7.  Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII.

Authors:  Walter H Dzik
Journal:  J Intensive Care Med       Date:  2006 Jan-Feb       Impact factor: 3.510

8.  Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.

Authors:  Kathryn A O'Connell; Jennifer J Wood; Robert P Wise; Jay N Lozier; M Miles Braun
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

9.  Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery.

Authors:  M Al Douri; T Shafi; D Al Khudairi; E Al Bokhari; L Black; N Akinwale; M Osman Musa; A Al Homaidhi; M Al Fagih; R Borum Andreasen
Journal:  Blood Coagul Fibrinolysis       Date:  2000-04       Impact factor: 1.276

10.  Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis.

Authors:  Keyvan Karkouti; W Scott Beattie; D N Wijeysundera; Terrence M Yau; Stuart A McCluskey; Mohammed Ghannam; David Sutton; Adriaan van Rensburg; Jacek Karski
Journal:  Transfusion       Date:  2005-01       Impact factor: 3.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.